The Aphrodisiac Test: What Happens When VigRX Goes Through a Controlled Lab Study?

The word aphrodisiac gets thrown around a lot. It shows up on product pages, in supplement marketing, and on the labels of things that have never been near a laboratory. VigRX took a different path.

In a formal preclinical study commissioned by AIBMR Life Sciences and conducted by Natural Remedies Private Limited, the VigRX tablet blend was evaluated for aphrodisiac activity using male albino Wistar rats under controlled, blinded conditions. The study ran for 14 days at three dose levels, with observations at days 1, 7, and 14.

How the Study Was Designed

Forty sexually active male rats were randomly assigned to five groups of eight animals each. One group received vehicle control (water), one received testosterone injection as the positive control, and three groups received VigRX orally at doses of 225, 335, and 450 mg/kg body weight. The doses were selected based on recommended human doses allometrically scaled to rat body weight.

Observers were blinded to treatment assignment. Copulatory behavior was recorded across seven parameters: mount latency, mount frequency, intromission latency, intromission frequency, ejaculation latency, ejaculation frequency, and post-ejaculatory interval.

After 14 days, blood was drawn to measure testosterone. Testes, epididymides, and seminal vesicles were collected for histopathological evaluation.

What the Data Showed: Dose-Dependent Effects Over Time

The most consistent finding across all three VigRX doses was a statistically significant reduction in ejaculation latency on day 14 (p < 0.05 versus vehicle control). This reduction was observed from the lowest dose through the highest. A shorter ejaculation latency reflects a more responsive and active sexual drive.
Post-ejaculatory interval was also significantly reduced at all VigRX doses on day 14 (p < 0.05 versus control). This is a meaningful finding in the assessment of sexual stamina and recovery.

At the highest dose of 450 mg/kg, additional significant effects emerged. Mount latency was significantly reduced by day 14. Intromission latency was significantly reduced on both days 7 and 14. Ejaculation frequency showed a significant increase on day 7.

At 450 mg/kg: significantly reduced mount latency (day 14), intromission latency (days 7 and 14), ejaculation latency (day 14), and post-ejaculatory interval (day 14). Ejaculation frequency significantly increased (day 7).

Testosterone and Histopathology

Serum testosterone showed a marginal, non-statistically significant increase in the two higher VigRX dose groups (335 and 450 mg/kg) compared to vehicle control. The testosterone-treated group showed a large and statistically significant increase as expected.

Histopathological examination of the testes, epididymides, and seminal vesicles revealed no significant differences between VigRX-treated and control animals. The number of spermatogonia cells in the seminiferous tubules showed a numerical increase in treated groups, though this did not reach statistical significance.

Histopathology: no adverse findings in reproductive tissues at any dose tested.

The Conclusion of the Study

The study investigators concluded that VigRX exhibited aphrodisiac activity by significantly reducing ejaculation latency and post-ejaculatory interval at all tested doses on day 14, and by significantly reducing mount latency and intromission latency at the highest dose. A marginal increase in testosterone concentration and spermatogonia cell counts was also observed.

These findings, taken alongside the purity and safety data from the companion Smitasiri et al. study, form part of the independent laboratory evidence supporting the formula's clinical plausibility.

Study Reference

Natural Remedies Private Limited. Evaluation of Aphrodisiac Activity of VigRx in Male Albino Wistar Rats. Report No. R401.07. Sponsored by AIBMR Life Sciences, Inc. Bangalore, India.

Click here to read the full report →
Explore the complete VigRX product line →